| Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China | |
| Huang, Jing; Mo, Hongnan; Zhang, Weilong; Chen, Xuelian; Qu, Dong; Wang, Xi; Wu, Dawei; Wang, Xingyuan; Lan, Bo; Yang, Beibei | |
| 2019 | |
| 卷号 | 125期号:5页码:742-749 |
| 关键词 | B7-H1 antigen DNA mismatch repair l-lactate dehydrogenase programmed cell death 1 receptor stomach neoplasms |
| ISSN号 | 0008-543X |
| DOI | 10.1002/cncr.31855 |
| URL标识 | 查看原文 |
| 收录类别 | SCIE ; PUBMED |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6345712 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Huang, Jing,Mo, Hongnan,Zhang, Weilong,et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J],2019,125(5):742-749. |
| APA | Huang, Jing.,Mo, Hongnan.,Zhang, Weilong.,Chen, Xuelian.,Qu, Dong.,...&Xu, Binghe.(2019).Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.,125(5),742-749. |
| MLA | Huang, Jing,et al."Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China".125.5(2019):742-749. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论